Gilead acquires XinThera to strengthen pipeline in oncology

Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors

FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS

Lucid-MS is a new drug candidate for the treatment of multiple sclerosis

Zion Pharma inks agreement with Roche to develop and commercialize brain-penetrable compounds

ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer

Baxter to sell its BioPharma Solutions Business to Advent International and Warburg Pincus for US $4.25billion

Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation

Merck plans bioprocessing center in South Korea

The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.

Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment

It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

PI Industries announces twin acquisitions into Pharma API & CDMO space

USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.